Systemic delivery of Eg5 shRNA-expressing plasmids using PEGylated DC-Chol/DOPE cationic liposome: Long-term silencing and anticancer effects in vivo

• Published in: Biochemical pharmacology 2019-08, Vol.166, p.192-202
• Main Authors: Seraj, Sharmin, Lee, Jinju, Ahn, Hyung Jun
• Format: Article
• Language: English
• Subjects: Animals; Antineoplastic Agents - administration & dosage; Cell Line, Tumor; Cholesterol - administration & dosage; Cholesterol - analogs & derivatives; Cholesterol - biosynthesis; Cholesterol - genetics; Female; Gene Expression; Gene Silencing - drug effects; Gene Silencing - physiology; Gene Transfer Techniques; Humans; Kinesin - administration & dosage; Kinesin - biosynthesis; Kinesin - genetics; Liposomes; Long-term silencing; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; PEGylated cationic liposome; Phosphatidylethanolamines - administration & dosage; Phosphatidylethanolamines - biosynthesis; Phosphatidylethanolamines - genetics; Plasmid-based shRNA expression; Plasmids - administration & dosage; Plasmids - biosynthesis; Plasmids - genetics; Random Allocation; RNA, Small Interfering - administration & dosage; RNA, Small Interfering - biosynthesis; RNA, Small Interfering - genetics; RNAi; ShRNA; Xenograft Model Antitumor Assays - methods
• ISSN: 0006-2952; 1873-2968
• DOI: 10.1016/j.bcp.2019.05.021

[Display omitted] Duration of gene silencing due to the short-term silencing effects induced by exogenous siRNA have limited the therapeutic applications of RNAi and the development of RNAi-based therapeutics. We here generated Eg5 shRNA-expressing plasmids using the inverted terminal repeats (ITRs) sequences to produce Eg5 hairpin RNA under the control of U6 promoter. Using PEGylated DC-Chol/DOPE cationic liposomes, we demonstrated that a single systemic administration of Eg5 shRNA-expressing plasmid/liposome lipoplexes induced the long-term Eg5 silencing in the tumor sites of tumor-bearing mice, and ultimately lead to more sustained anticancer effects than standard synthetic siEg5/liposome lipoplexes. This non-viral Eg5 shRNA expression system had no risk of immunogenicity anticipated in the use of viral vectors, and could reduce the potential of off-target effects by scaling down the administration dose of RNAi therapeutics in patient. Therefore, the sustainable shRNA expression properties in the tumor sites suggest an efficient strategy to overcome the limitations caused by chemically synthesized siRNA methods such as short-term silencing effects and off-target effects. Herein, this study provides a non-viral silencing strategy for inducing long-term Eg5 silencing in vivo and suggests the great potential of Eg5 shRNA-expressing lipoplexes as a DNA-based RNAi therapeutics for cancer treatment.